Earnings Reportpositive
Earnings Report
- Company
- Nuvation Bio Inc. (NUVB)
Other upcoming events for NUVB
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kina
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine i
Patent ExpiryPatent/Exclusivity Expiry: IBTROZI
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.